Prior to joining Fidelity in 2005, Dr. Li focused his effort on healthcare and life science investment opportunities at Baird Venture Partners, the venture capital arm of R.W.Baird. Prior to Baird, he led drug discovery projects and technology licensing due diligence at Vertex Pharmaceuticals, a small-molecule therapeutic company based in Cambridge, MA. He also worked in strategic marketing at Serono International S.A., a biopharmaceutical company based in Geneva, Switzerland. During his scientific career, Wei first-authored numerous scientific publications in journals including Science, Proceedings of the National Academy of Sciences, and Journal of Biological Chemistry.

Wei received a B.S., with distinction, in Chemical Physics from University of Science and Technology of China, a Ph.D. in Biochemistry and Mammalian Genetics from Harvard University, and an MBA from the Kellogg School of Management at Northwestern University, where he was elected Beta Gamma Sigma, with a concentration in Finance, Accounting and Marketing. Dr. Li serves on the Board of Directors of TCT Medical and Innovent Biologics.